Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Bolt Biotherapeutics, Inc. (BOLT)
Company Research
Source: GlobeNewswire
Presentation of preclinical data supporting the selection of BDC-2034, an ISAC targeting CEA, as Bolt Biotherapeutics’ second Boltbody™ ISAC development candidateDemonstration of the novel, multifunctional mechanism for an ISAC which combines PD-1/PD-L1 axis inhibition with TLR agonismIdentification of novel agonist antibodies targeting Dectin-2, now revealed as Bolt Biotherapeutics’ TAM1 target, designed to reprogram tumor-supportive macrophages into tumor-destructive macrophages REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the company will be presenting posters with new data from three of its pipeline programs on Saturday, Nov. 13, at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held
Show less
Read more
Impact Snapshot
Event Time:
BOLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BOLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BOLT alerts
High impacting Bolt Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BOLT
News
- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateGlobeNewswire
- Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceGlobeNewswire
BOLT
Earnings
- 11/9/23 - Beat
BOLT
Analyst Actions
- 3/22/24 - HC Wainwright
BOLT
Sec Filings
- 3/21/24 - Form S-8
- 3/21/24 - Form 10-K
- 3/21/24 - Form 8-K
- BOLT's page on the SEC website